This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...
There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...
Sanofi has just spent $16 billion on acquiring ... ($6.97 billion), led by its Myozyme/Lumizyme franchise. The new acquisitions, Bioverativ and Ablynx, are also part of the growth plan, and ...
He added that while there was no timeline for how long Sanofi would be involved in Opella, "we expect to be involved and in partnership for a long time". Opella employs 11,000 people globally and ...
Before the Sanofi acquisition closes, Inhibrx will spin off its other drug assets, which target various cancers, into a company to be called New Inhibrx. That firm will have $200 million in cash ...
Crossmark Global Holdings Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 23.7% during the ...
Hosted on MSN9mon
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx ProjectThe acquisition of INBRX-101 is seen as a step towards strengthening Sanofi’s rare disease business. Following the acquisition, New Inhibrx will continue to operate under the “Inhibrx” name ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback